Kisqali is indicated for the treatment of postmenopausal women with hormone receptor-positive (HR+) and human epidermal growth factor receptor type 2 receptor-negative (HER2-) advanced or metastatic breast cancer.
Active ingredient: ribociclib
Prescription medicine